For instance, the carcinoembryonic antigen (CEA) in colorectal cancer patients [37] and prostate-specific membrane antigen (PSMA) in patients with metastatic cancers [38], respectively, demonstrated good safety profiles although the immunogenicity responses have been modest. The gene discussed is CEACAM5; the disease is colorectal cancer.